Fimasartan (original) (raw)
Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea on September 9, 2010, and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership.
| Property | Value |
|---|---|
| dbo:abstract | Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea on September 9, 2010, and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership. (en) Fimasartan (łac. fimasartanum) – wielofunkcyjny organiczny związek chemiczny, lek stosowany w leczeniu nadciśnienia tętniczego, hamujący działanie angiotensyny II poprzez blokadę receptora angiotensynowego typu 1 (AT1). (pl) |
| dbo:alternativeName | Kanarb (en) |
| dbo:casNumber | 247257-48-3 |
| dbo:chEMBL | 1951143 |
| dbo:fdaUniiCode | P58222188P |
| dbo:kegg | D10556 |
| dbo:pubchem | 9870652 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Fimasartan_skeletal.svg?width=300 |
| dbo:wikiPageID | 38844653 (xsd:integer) |
| dbo:wikiPageLength | 10616 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1098218202 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Endothelin_1 dbr:Blood_pressure dbr:Hydrochlorothiazide dbr:Hypertension dbr:Renin dbr:Myocardial_infarction dbr:Angiotensin_II dbr:Stroke dbr:Heart_failure dbr:Aldosterone dbr:Angiotensin-converting_enzyme dbr:Angiotensin_II_receptor_type_1 dbr:Angiotensinogen dbr:Vasodilation dbc:Thioamides dbr:Half-life dbr:Angiotensin_I dbr:Angiotensin_II_receptor_antagonist dbc:Angiotensin_II_receptor_antagonists dbr:Bile dbr:Blood_volume dbr:T-max dbr:Vasoconstriction dbr:TGF-β1 |
| dbp:atcPrefix | 9.0 |
| dbp:atcSuffix | CA10 (en) |
| dbp:c | 27 (xsd:integer) |
| dbp:casNumber | 247257 (xsd:integer) |
| dbp:chembl | 1951143 (xsd:integer) |
| dbp:chemspiderid | 8046343 (xsd:integer) |
| dbp:h | 31 (xsd:integer) |
| dbp:iupacName | 2 (xsd:integer) |
| dbp:kegg | D10556 (en) |
| dbp:n | 7 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 9870652 (xsd:integer) |
| dbp:s | 1 (xsd:integer) |
| dbp:smiles | CCCCC1=NCC (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | AMEROGPZOLAFBN-UHFFFAOYSA-N (en) |
| dbp:tradename | Kanarb (en) |
| dbp:unii | P58222188P (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_drug dbt:Reflist dbt:Short_description dbt:Keggcite dbt:ACE_inhibitors dbt:Angiotensin_receptor_modulators |
| dcterms:subject | dbc:Thioamides dbc:Angiotensin_II_receptor_antagonists |
| gold:hypernym | dbr:Antagonist |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Chemical114806838 yago:Compound114818238 yago:Element114840755 yago:Ester114850483 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:WikicatEthylEsters yago:WikicatPhenolEthers |
| rdfs:comment | Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea on September 9, 2010, and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership. (en) Fimasartan (łac. fimasartanum) – wielofunkcyjny organiczny związek chemiczny, lek stosowany w leczeniu nadciśnienia tętniczego, hamujący działanie angiotensyny II poprzez blokadę receptora angiotensynowego typu 1 (AT1). (pl) |
| rdfs:label | Fimasartan (en) Fimasartan (pl) |
| owl:sameAs | freebase:Fimasartan wikidata:Fimasartan dbpedia-pl:Fimasartan https://global.dbpedia.org/id/51FJL |
| prov:wasDerivedFrom | wikipedia-en:Fimasartan?oldid=1098218202&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Fimasartan_skeletal.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Fimasartan |
| is dbo:wikiPageRedirects of | dbr:Kanarb |
| is dbo:wikiPageWikiLink of | dbr:Antihypertensive_drug dbr:Kanarb dbr:Angiotensin_II_receptor_blocker dbr:List_of_Korean_inventions_and_discoveries dbr:ATC_code_C09 dbr:ATC_code_C10 dbr:List_of_drugs:_Fi |
| is foaf:primaryTopic of | wikipedia-en:Fimasartan |
